Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

AI Sentiment AnalystBuy
Sentiment Score7/10
Generated At:2026-03-04 16:37:11
Analysis based on 20 news articles from Yahoo Finance and other financial news sources published around March 4, 2026, covering Pfizer's oncology developments, dividend performance, valuation metrics, competitive landscape, and market performance data. Data includes YTD performance metrics, clinical trial results, dividend yield analysis, and competitive intelligence.
News Overview

Positive oncology developments and dividend appeal expected to drive +2% to +4% short-term price appreciation, with potential +3% to +6% upside from continued oncology momentum, recommending buy for income investors and oncology-driven growth.

Positive
2
Neutral
2
Negative
0
Event Timeline
2026-03-04
Price Impact: +3% to +6%
medium-term
Pfizer achieved significant oncology milestones in March 2026 with positive Phase 3 results for PADCEV + Keytruda in muscle-invasive bladder cancer showing reduced recurrence/death risk and higher complete response rates, plus full FDA approval of BRAFTOVI-based regimen for BRAF V600E-mutant metastatic colorectal cancer, positioning the company strongly in oncology markets
2026-03-04
Price Impact: +1% to +3%
long-term
Pfizer's 6.3% dividend yield remains highly attractive to income investors in March 2026, supported by strong total shareholder returns of 10.72% over 1 year and 21.03% over 3 years, providing income stability compared to competitors
2026-03-04
Price Impact: 0% to +2%
short-term
Pfizer demonstrated strong market performance in early 2026 with +11% YTD rally, +2.49% 1-day and +2.06% 7-day gains, while DCF-based valuations suggest potential undervaluation despite concerns about flat 2026 guidance and patent expirations
2026-03-04
Price Impact: 0% to -2%
medium-term
The competitive landscape shows Moderna's $2.25 billion patent settlement removing legal overhang in March 2026, while Eli Lilly's GLP-1 dominance contrasts with Pfizer's oncology and dividend focus, and J&J's growth in immunology/neuroscience highlights industry diversification beyond COVID-19
News Topics List

Oncology Breakthroughs Driving Growth

2026-03-04positivePrice Impact: +3% to +6%medium-term
AI Key Summary
  • Positive Phase 3 results for PADCEV + Keytruda in muscle-invasive bladder cancer (EV-304 trial) show significant clinical benefits
  • Results include reduced recurrence/death risk and higher complete response rates
  • This positions Pfizer strongly in the oncology market alongside partner Astellas
  • Full FDA approval of BRAFTOVI-based regimen for BRAF V600E-mutant metastatic colorectal cancer enhances Pfizer's oncology portfolio
  • These milestones are critical for offsetting post-COVID revenue declines
Source
  • Pfizer Inc. and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer
  • Pfizer Oncology Milestones Reshape Outlook Beyond COVID-19 Revenues

Dividend Appeal & Income Investor Focus

2026-03-04positivePrice Impact: +1% to +3%long-term
AI Key Summary
  • Pfizer's 6.3% dividend yield is highlighted as a key attraction for income investors
  • Strong total shareholder returns of 10.72% over 1 year and 21.03% over 3 years underscore income stability
  • Dividend appeal compares favorably to competitors like Teva
  • Income investors see Pfizer as a value buy with reliable dividend payments
Source
  • Forget Teva: This Dividend Top Dog Is the Real Value Buy Today
  • 1 Reason I'd Happily Buy Pfizer (PFE) Stock and Never Sell

Valuation & Market Performance

2026-03-04neutralPrice Impact: 0% to +2%short-term
AI Key Summary
  • Recent performance shows +2.49% 1-day and +2.06% 7-day gains
  • Year-to-date performance shows +5.56% in 2026
  • Long-term returns show +10.72% over 1 year and +21.03% over 3 years
  • DCF-based valuations suggest potential undervaluation
  • Flat 2026 guidance and patent expirations remain concerns
Source
  • A Look At Pfizer (PFE) Valuation As Long Term Returns And DCF Views Diverge
  • Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?

Competitive Landscape & Industry Dynamics

2026-03-04neutralPrice Impact: 0% to -2%medium-term
AI Key Summary
  • Moderna's patent settlement of $2.25 billion removes legal overhang but highlights competitive pressure
  • Eli Lilly's GLP-1 dominance contrasts with Pfizer's focus on oncology and dividends
  • J&J's growth in immunology/neuroscience shows industry diversification beyond COVID-19
  • Competitive pressures exist in vaccine markets despite patent settlements
Source
  • Moderna Rises as Up to $2.25 Billion Settlement for COVID Vaccine Patent Dispute to Remove Overhang
  • Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?